Omega-3 in the treatment of schizophrenia

Phase 2

• Conditions: schizophrenia.; Schizophrenia

• Registration Number: IRCT138811022935N3
• Lead Sponsor: Kurdistan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 36

Inclusion Criteria

Inclusion Criteria: Age between 18 and 60, diagnosis of Schizophrenia based on DSM IV, chronic Schizophrenia

Exclusion Criteria

Substance dependence, any serious medical problem

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of schizophrenia. Timepoint: Baseline and 6 months after beginnig of treatmen. Method of measurement: Positive and Negative Syndrome Scale (PANSS).